Research progress of computer aided diagnosis system for pulmonary nodules in CT images

How AI Can Help in the Diagnostic Dilemma of Pulmonary Nodules

Simple Summary

Pulmonary nodules are considered a sign of bronchogenic carcinoma, detecting them early will reduce their progression and can save lives. Lung cancer is the second most common type of cancer in both men and women. This manuscript discusses the current applications of artificial intelligence (AI) in lung segmentation as well as pulmonary nodule segmentation and classification using computed tomography (CT) scans, published in the last two decades, in addition to the limitations and future prospects in the field of AI.

Abstract

Pulmonary nodules are the precursors of bronchogenic carcinoma, its early detection facilitates early treatment which save a lot of lives. Unfortunately, pulmonary nodule detection and classification are liable to subjective variations with high rate of missing small cancerous lesions which opens the way for implementation of artificial intelligence (AI) and computer aided diagnosis (CAD) systems. The field of deep learning and neural networks is expanding every day with new models designed to overcome diagnostic problems and provide more applicable and simply used models. We aim in this review to briefly discuss the current applications of AI in lung segmentation, pulmonary nodule detection and classification.

Assessing the predictive accuracy of lung cancer, metastases, and benign lesions using an artificial intelligence-driven computer aided diagnosis system

Background

Artificial intelligence (AI) products have been widely used for the clinical detection of primary lung tumors. However, their performance and accuracy in risk prediction for metastases or benign lesions remain underexplored. This study evaluated the accuracy of an AI-driven commercial computer-aided detection (CAD) product (InferRead CT Lung Research, ICLR) in malignancy risk prediction using a real-world database.

Methods

This retrospective study assessed 486 consecutive resected lung lesions, including 320 adenocarcinomas, 40 other malignancies, 55 metastases, and 71 benign lesions, from September 2015 to November 2018. The malignancy risk probability of each lesion was obtained using the ICLR software based on a 3D convolutional neural network (CNN) with DenseNet architecture as a backbone (without clinical data). Two resident doctors independently graded each lesion using patient clinical history. One doctor (R1) has 3 years of chest radiology experience, and the other doctor (R2) has 3 years of general radiology experience. Cochran's Q test was used to assess the performances of the AI compared to the radiologists.

Results

The accuracy of malignancy-risk prediction using the ICLR for adenocarcinomas, other malignancies, metastases, and benign lesions was 93.4% (299/320), 95.0% (38/40), 50.9% (28/55), and 40.8% (29/71), respectively. The accuracy was significantly higher in adenocarcinomas and other malignancies compared to metastases and benign lesions (all P<0.05). The overall accuracy of risk prediction for R1 was 93.6% (455/486) and 87.4% for R2 (425/486), both of which were higher than the 81.1% accuracy obtained with the ICLR (394/486) (R1 vs. ICLR: P<0.001; R2 vs. ICLR: P=0.001), especially in assessing the risk of metastases (P<0.05). R1 performed better than R2 at risk prediction (P=0.001).

Conclusions

The accuracy of the ICLR for risk prediction is very high for primary lung cancers but poor for metastases and benign lesions.